This document provides information about the 8th Annual Symposium on Early Alzheimer's Disease that will take place on March 12-13, 2010 in Miami Beach, Florida. The symposium will focus on mild cognitive impairment and preclinical Alzheimer's disease, with sessions on interpreting psychometric test results, biomarkers for early detection, and results from longitudinal studies. National experts will present the latest research. The target audience is medical professionals working with dementia patients. Registration information is provided.
This document provides an agenda for the 10th Annual Symposium on Mild Cognitive Impairment and the 1st Early Alzheimer's Diagnostic Workshop being held January 14-15, 2012 in Miami Beach, Florida. The symposium and workshop will focus on advances in the clinical diagnosis and progression of Alzheimer's disease and related disorders, with an emphasis on the early stages of the disease. Over the two-day event, there will be keynote speeches and panel discussions on topics such as atypical presentations of Alzheimer's, the prion-like progression of the disease, and new concepts in pathogenesis. The goal is to help clinicians more accurately diagnose Alzheimer's and related conditions earlier.
This document provides information about the Mild Cognitive Impairment (MCI) Symposium that will take place from March 7-8, 2008 in Miami Beach, Florida. The symposium will focus on disease modifying treatments for Alzheimer's disease. It will feature expert speakers discussing biomarkers for measuring progression and treatment effects in Alzheimer's, pathogenic mechanisms of cognitive impairment, non-pharmacological treatments, and potential disease-modifying pharmaceutical agents. The target audience is medical professionals in fields related to neurology and geriatrics. The symposium will provide updates on the latest research and allow for discussion on improving diagnosis and treatment of early-stage Alzheimer's.
This document summarizes the agenda and objectives for the 2nd Annual Mild Cognitive Impairment Symposium being held on February 27-28, 2004 in Miami Beach, Florida. The symposium consists of an educational module on day one and a research module on day two. Both modules will focus on understanding and detecting mild cognitive impairment, with objectives around diagnosis, subtypes, biomarkers, imaging, and screening tools. The symposium is sponsored by Mount Sinai Medical Center and aims to promote early detection and treatment of dementia.
The document provides information about the 9th Annual Symposium on Mild Cognitive Impairment that will take place on April 29-30, 2011 in Miami Beach, Florida. It includes the agenda, list of distinguished faculty, registration information, and logistical details about the event. The symposium will focus on new criteria for prodromal and preclinical Alzheimer's disease, with sessions on risk factors, diagnosis and progression of mild cognitive impairment and preclinical Alzheimer's disease.
This document provides information about an upcoming symposium on Mild Cognitive Impairment (MCI). It will take place February 24-25, 2006 at the Eden Roc Resort & Spa in Miami Beach, Florida. The symposium is sponsored by several Alzheimer's research centers and will feature over 40 expert speakers. The goal is to provide the latest information on diagnosing and treating MCI, as well as discussing related topics like cognitive reserve, genetics, and vascular/medical factors. The symposium offers 15 hours of continuing education credits for physicians and psychologists.
This document provides information about the 7th Annual Mild Cognitive Impairment Symposium that will take place on March 27-28, 2009 in Miami, Florida. The symposium will focus on early Alzheimer's disease and non-Alzheimer's prodromal dementias. It will feature keynote speakers and breakout sessions on topics such as vascular cognitive impairment, prevention and treatment of mild cognitive impairment and early Alzheimer's, and distinguishing between early Lewy body disease and Alzheimer's disease. The document provides details on registration, continuing education credits, the agenda, faculty members, and objectives of the symposium.
This document announces a symposium on Mild Cognitive Impairment (MCI) that will provide 15 hours of continuing education credits for physicians and psychologists, featuring experts who will present on the causes, detection, and treatment of early dementia; it discloses any relationships between faculty and industry sponsors, and provides contact information for the symposium.
This document provides information about the Mild Cognitive Impairment (MCI) Symposium that will take place from April 13-14, 2007 in Miami Beach, Florida. The symposium, directed by Dr. Ranjan Duara, will focus on developing earlier diagnosis of Alzheimer's disease and feature experts in fields related to dementia. Over two days, speakers will present on topics such as the pathology of aging and prodromal Alzheimer's, diagnosis of early Alzheimer's in clinical and research settings, and algorithms for integrating elements to achieve earlier diagnosis. The goal is to promote better understanding of diagnosing Alzheimer's disease earlier in its progression.
This document provides an agenda for the 10th Annual Symposium on Mild Cognitive Impairment and the 1st Early Alzheimer's Diagnostic Workshop being held January 14-15, 2012 in Miami Beach, Florida. The symposium and workshop will focus on advances in the clinical diagnosis and progression of Alzheimer's disease and related disorders, with an emphasis on the early stages of the disease. Over the two-day event, there will be keynote speeches and panel discussions on topics such as atypical presentations of Alzheimer's, the prion-like progression of the disease, and new concepts in pathogenesis. The goal is to help clinicians more accurately diagnose Alzheimer's and related conditions earlier.
This document provides information about the Mild Cognitive Impairment (MCI) Symposium that will take place from March 7-8, 2008 in Miami Beach, Florida. The symposium will focus on disease modifying treatments for Alzheimer's disease. It will feature expert speakers discussing biomarkers for measuring progression and treatment effects in Alzheimer's, pathogenic mechanisms of cognitive impairment, non-pharmacological treatments, and potential disease-modifying pharmaceutical agents. The target audience is medical professionals in fields related to neurology and geriatrics. The symposium will provide updates on the latest research and allow for discussion on improving diagnosis and treatment of early-stage Alzheimer's.
This document summarizes the agenda and objectives for the 2nd Annual Mild Cognitive Impairment Symposium being held on February 27-28, 2004 in Miami Beach, Florida. The symposium consists of an educational module on day one and a research module on day two. Both modules will focus on understanding and detecting mild cognitive impairment, with objectives around diagnosis, subtypes, biomarkers, imaging, and screening tools. The symposium is sponsored by Mount Sinai Medical Center and aims to promote early detection and treatment of dementia.
The document provides information about the 9th Annual Symposium on Mild Cognitive Impairment that will take place on April 29-30, 2011 in Miami Beach, Florida. It includes the agenda, list of distinguished faculty, registration information, and logistical details about the event. The symposium will focus on new criteria for prodromal and preclinical Alzheimer's disease, with sessions on risk factors, diagnosis and progression of mild cognitive impairment and preclinical Alzheimer's disease.
This document provides information about an upcoming symposium on Mild Cognitive Impairment (MCI). It will take place February 24-25, 2006 at the Eden Roc Resort & Spa in Miami Beach, Florida. The symposium is sponsored by several Alzheimer's research centers and will feature over 40 expert speakers. The goal is to provide the latest information on diagnosing and treating MCI, as well as discussing related topics like cognitive reserve, genetics, and vascular/medical factors. The symposium offers 15 hours of continuing education credits for physicians and psychologists.
This document provides information about the 7th Annual Mild Cognitive Impairment Symposium that will take place on March 27-28, 2009 in Miami, Florida. The symposium will focus on early Alzheimer's disease and non-Alzheimer's prodromal dementias. It will feature keynote speakers and breakout sessions on topics such as vascular cognitive impairment, prevention and treatment of mild cognitive impairment and early Alzheimer's, and distinguishing between early Lewy body disease and Alzheimer's disease. The document provides details on registration, continuing education credits, the agenda, faculty members, and objectives of the symposium.
This document announces a symposium on Mild Cognitive Impairment (MCI) that will provide 15 hours of continuing education credits for physicians and psychologists, featuring experts who will present on the causes, detection, and treatment of early dementia; it discloses any relationships between faculty and industry sponsors, and provides contact information for the symposium.
This document provides information about the Mild Cognitive Impairment (MCI) Symposium that will take place from April 13-14, 2007 in Miami Beach, Florida. The symposium, directed by Dr. Ranjan Duara, will focus on developing earlier diagnosis of Alzheimer's disease and feature experts in fields related to dementia. Over two days, speakers will present on topics such as the pathology of aging and prodromal Alzheimer's, diagnosis of early Alzheimer's in clinical and research settings, and algorithms for integrating elements to achieve earlier diagnosis. The goal is to promote better understanding of diagnosing Alzheimer's disease earlier in its progression.
Washington State has a high rate of Alzheimer's disease deaths that is expected to increase 40% in the next 10 years. Many practices in the state lack guidelines for screening, diagnosing, and treating Alzheimer's and other dementias. The presentation discusses the Virginia Mason Cognitive Care in Primary Care program which provides resources and tools for a multidisciplinary approach to improve diagnosis, care, support, and planning for patients with cognitive issues. It also reviews diagnostic criteria and treatment approaches for vascular cognitive impairment, a common cause of dementia.
This document discusses chronic disease management and the potential of preventive, predictive, and personalized (3P) medicine. It notes that chronic diseases are a leading cause of disability and healthcare costs. The 3P approach aims to detect diseases earlier through screening and biomarkers, enable targeted prevention, and develop personalized treatment plans. This could substantially improve quality of life while potentially reducing costs through earlier intervention and improved management of chronic conditions.
The document summarizes the experiences of students who participated in the 2010 MSTAR (Medical Student Training in Aging Research) Program Graduation. It provides short quotes from each student about how the program increased their interest in geriatrics and academic medicine. They observed various aspects of geriatric care and research. The students appreciated learning from the passionate faculty and seeing how geriatricians provide comprehensive, compassionate care for older patients.
Deciding When Hospice Care is Needed | VITAS HealthcareVITAS Healthcare
The goal of this webinar is to help healthcare professionals address the specific challenges of end-of-life care when determining a terminal prognosis, so they can provide the optimum care for the patient and family during the final stages of life.
Developmental Disabilities and Community LifeRoss Finesmith
This document discusses community-based treatment of epilepsy in developmentally disabled individuals. It notes higher incidence of difficult-to-control seizures and limited ability for testing in this population. It reviews factors like legal guardians, family involvement, group home staff, and challenges of medication administration and testing. It provides guidance on antiepileptic drug selection considering efficacy, side effects, and treating co-morbid conditions.
This document discusses community-based treatment of epilepsy in developmentally disabled individuals. It notes that many principles of antiepileptic drug therapy for non-disabled individuals also apply to those with developmental disabilities, but that treating physicians face additional challenges. These include a higher rate of difficult-to-control seizures, limited ability to do diagnostic testing due to cognitive impairments, and greater risk of adverse drug effects. It also discusses the trend toward deinstitutionalization and relocation of developmentally disabled individuals to community settings, increasing the need for community physicians to treat their medical issues like epilepsy. The role of legal guardians, family members, and group home staff in providing care and information is also covered.
This document discusses community-based treatment of epilepsy in developmentally disabled individuals. It notes higher incidence of difficult-to-control seizures and potential for adverse effects from medications. Care is now provided in community settings like group homes rather than institutions. Physicians must work with legal guardians, family members, and caregivers to effectively manage patients' epilepsy and understand historical factors. Choosing antiepileptic drugs requires considering seizure type, psychiatric comorbidities, previous medication responses, and ability to administer medications properly in community settings. Neurodiagnostic testing can be challenging but helps identify seizure type and guide treatment.
Evaluation and Management of Behaviors in Persons with Cognitive ImpairmentVITAS Healthcare
The goal of this webinar is to enable healthcare clinicians to implement a comprehensive approach to non-pharmacologic and pharmacologic management of dementia-related behaviors for the benefit of patients and their caregivers.
This document discusses community-based treatment of epilepsy in developmentally disabled individuals. It notes higher incidence of difficult-to-control seizures and potential for adverse effects from medications in this population. It reviews factors like legal guardians, family involvement, group home staff, and challenges with diagnostic testing. It provides guidance on antiepileptic drug selection considering efficacy, side effects, and treatment of any co-morbid conditions.
The goal of this webinar was to help hospice and healthcare professionals understand the ethics and application of artificial nutrition and hydration (ANH) for patients near the end of life.
DR CHRISTOS KOUIMTSIDIS - ALCOHOL MISUSE IN SPECIAL POPULATIONS: INTELLECTUAL...iCAADEvents
There is little and con icting evidence on the prevalence of alcohol misuse and treatment available for people with Intellectual Disabilities (also referred as Learning Disabilities). As is similar to other vulnerable populations, adults with ID have increasingly lived more independently in the community following the closure of long-stay hospitals. This has increased their exposure to environmental stressors and substance and alcohol misuse, negatively impacting on their functioning, relationships, physical and mental health, and safety. Traumatic Brain Injury (TBI) is the most common cause of disability in younger adults. Yet the community care for patients with TBI varies hugely in the UK. There is a well-established link between TBI and alcohol misuse, with both TBI leading to increased levels of alcohol misuse and alcohol misuse contributing to risk of TBIs. The effects of neuronal damage have been shown to increase after TBI accompanied by alcohol intoxication.This presentation is based on the experience gained from the rst in the UK feasibility study on this topic, and draws from the experience of setting up and running the first ever pilot of a combined TBI and alcohol brief intervention service in London.
Why screeing cancer patients for distress will increase disparities in psycho...James Coyne
Keynote address
Implementing screening of cancer patients for distress will not improve patient outcomes and may aggravate existing biases in who get psychosocial services.
“Neurologic deficits
are frequently seen
in patients with
stroke. One of this is
a motor deficit
which is the
weakness of the
body. Another one is
an emotional deficit
which is
depression.”
Patient X has
decreased appetite
before
hospitalization
because of
depression due to
his condition. But
now he is willing to
eat during
hospitalization
because of proper
Page 7 of 38
pagkain...”
2. Hygiene
Daughter
verbalized:
“Hindi na siya
makapag-ayos
ng sarili...”
Needs minimal
assistance in
bathing and
g
Respiratory Symptoms in the Terminally Ill PatientVITAS Healthcare
The goal of this webinar was to educate healthcare professionals on interventions for cough, dyspnea, hemoptysis, and the “death rattle” in patients with end-of-life respiratory symptoms.
The document discusses the career path and experiences of a family physician. It describes their journey from high school through medical school and residency training. As a family physician, they provide comprehensive primary care to patients of all ages, conduct a wide range of medical procedures, and value building long-term relationships with patients to support their overall health and well-being.
The document describes a case study of a 66-year-old female patient who suffered an ischemic stroke affecting the middle cerebral artery. She experienced left-sided weakness and expressive aphasia. Initial evaluation found she had oropharyngeal dysphagia and aspiration even with nectar thick liquids. She received intensive speech and swallowing therapy, making progress until being discharged to an inpatient rehabilitation facility for further recovery.
Annals of Behavioral Medicine Volume 49-Issue 1 Supplement-April 2015Monique Tsang, BS, CNA
This seminar provides an overview of a pilot bibliotherapy program for survivors of acquired brain injury (ABI) and individuals with chronic pain or disability. The program was started in 2012 at Erie County Medical Center in Buffalo, NY and has shown benefits to quality of life and symptom reduction. The seminar will present qualitative data on the impact of the program and provide details on its development, mission statement, recruitment process, book selection, and collaboration with rehabilitation and behavioral health services. Bibliotherapy shows potential as a cost-effective and sustainable treatment approach to target common deficits after ABI or injury such as reduced empathy, poor perspective taking, and impaired information processing.
Annals of behavioral medicine volume 49 issue 1 supplement april 2015Monique Tsang, BS, CNA
The current study investigated whether a single presentation on sleep hygiene could result in improvement in reported sleep quality and quantity for undergraduate students newly entering university.
This curriculum vitae summarizes Jeffrey S. Gerdes' professional experience and education. It lists that he has been the chiropractor and clinical director of Carolina ChiroCare and Rehab Inc. in Raleigh, NC since 2010. It also notes that he received his doctorate of chiropractic from Palmer College of Chiropractic Florida in 2008. The CV provides details on his licensure, certifications, and extensive postgraduate education, including courses on MRI interpretation, neurological emergencies, and assessing medical fitness to return to work.
The document summarizes a course on recent advances in the diagnosis and management of kidney cancer. The course was held on May 17, 2008 from 6-8 pm as part of the American Urological Association's annual meeting. It was directed by Dr. W. Marston Linehan from the National Cancer Institute and included presentations by Dr. Peter Pinto from the National Cancer Institute and Dr. Jeffrey Sosman from Vanderbilt University. The course provided an overview of new developments in diagnosing and treating kidney cancer.
Washington State has a high rate of Alzheimer's disease deaths that is expected to increase 40% in the next 10 years. Many practices in the state lack guidelines for screening, diagnosing, and treating Alzheimer's and other dementias. The presentation discusses the Virginia Mason Cognitive Care in Primary Care program which provides resources and tools for a multidisciplinary approach to improve diagnosis, care, support, and planning for patients with cognitive issues. It also reviews diagnostic criteria and treatment approaches for vascular cognitive impairment, a common cause of dementia.
This document discusses chronic disease management and the potential of preventive, predictive, and personalized (3P) medicine. It notes that chronic diseases are a leading cause of disability and healthcare costs. The 3P approach aims to detect diseases earlier through screening and biomarkers, enable targeted prevention, and develop personalized treatment plans. This could substantially improve quality of life while potentially reducing costs through earlier intervention and improved management of chronic conditions.
The document summarizes the experiences of students who participated in the 2010 MSTAR (Medical Student Training in Aging Research) Program Graduation. It provides short quotes from each student about how the program increased their interest in geriatrics and academic medicine. They observed various aspects of geriatric care and research. The students appreciated learning from the passionate faculty and seeing how geriatricians provide comprehensive, compassionate care for older patients.
Deciding When Hospice Care is Needed | VITAS HealthcareVITAS Healthcare
The goal of this webinar is to help healthcare professionals address the specific challenges of end-of-life care when determining a terminal prognosis, so they can provide the optimum care for the patient and family during the final stages of life.
Developmental Disabilities and Community LifeRoss Finesmith
This document discusses community-based treatment of epilepsy in developmentally disabled individuals. It notes higher incidence of difficult-to-control seizures and limited ability for testing in this population. It reviews factors like legal guardians, family involvement, group home staff, and challenges of medication administration and testing. It provides guidance on antiepileptic drug selection considering efficacy, side effects, and treating co-morbid conditions.
This document discusses community-based treatment of epilepsy in developmentally disabled individuals. It notes that many principles of antiepileptic drug therapy for non-disabled individuals also apply to those with developmental disabilities, but that treating physicians face additional challenges. These include a higher rate of difficult-to-control seizures, limited ability to do diagnostic testing due to cognitive impairments, and greater risk of adverse drug effects. It also discusses the trend toward deinstitutionalization and relocation of developmentally disabled individuals to community settings, increasing the need for community physicians to treat their medical issues like epilepsy. The role of legal guardians, family members, and group home staff in providing care and information is also covered.
This document discusses community-based treatment of epilepsy in developmentally disabled individuals. It notes higher incidence of difficult-to-control seizures and potential for adverse effects from medications. Care is now provided in community settings like group homes rather than institutions. Physicians must work with legal guardians, family members, and caregivers to effectively manage patients' epilepsy and understand historical factors. Choosing antiepileptic drugs requires considering seizure type, psychiatric comorbidities, previous medication responses, and ability to administer medications properly in community settings. Neurodiagnostic testing can be challenging but helps identify seizure type and guide treatment.
Evaluation and Management of Behaviors in Persons with Cognitive ImpairmentVITAS Healthcare
The goal of this webinar is to enable healthcare clinicians to implement a comprehensive approach to non-pharmacologic and pharmacologic management of dementia-related behaviors for the benefit of patients and their caregivers.
This document discusses community-based treatment of epilepsy in developmentally disabled individuals. It notes higher incidence of difficult-to-control seizures and potential for adverse effects from medications in this population. It reviews factors like legal guardians, family involvement, group home staff, and challenges with diagnostic testing. It provides guidance on antiepileptic drug selection considering efficacy, side effects, and treatment of any co-morbid conditions.
The goal of this webinar was to help hospice and healthcare professionals understand the ethics and application of artificial nutrition and hydration (ANH) for patients near the end of life.
DR CHRISTOS KOUIMTSIDIS - ALCOHOL MISUSE IN SPECIAL POPULATIONS: INTELLECTUAL...iCAADEvents
There is little and con icting evidence on the prevalence of alcohol misuse and treatment available for people with Intellectual Disabilities (also referred as Learning Disabilities). As is similar to other vulnerable populations, adults with ID have increasingly lived more independently in the community following the closure of long-stay hospitals. This has increased their exposure to environmental stressors and substance and alcohol misuse, negatively impacting on their functioning, relationships, physical and mental health, and safety. Traumatic Brain Injury (TBI) is the most common cause of disability in younger adults. Yet the community care for patients with TBI varies hugely in the UK. There is a well-established link between TBI and alcohol misuse, with both TBI leading to increased levels of alcohol misuse and alcohol misuse contributing to risk of TBIs. The effects of neuronal damage have been shown to increase after TBI accompanied by alcohol intoxication.This presentation is based on the experience gained from the rst in the UK feasibility study on this topic, and draws from the experience of setting up and running the first ever pilot of a combined TBI and alcohol brief intervention service in London.
Why screeing cancer patients for distress will increase disparities in psycho...James Coyne
Keynote address
Implementing screening of cancer patients for distress will not improve patient outcomes and may aggravate existing biases in who get psychosocial services.
“Neurologic deficits
are frequently seen
in patients with
stroke. One of this is
a motor deficit
which is the
weakness of the
body. Another one is
an emotional deficit
which is
depression.”
Patient X has
decreased appetite
before
hospitalization
because of
depression due to
his condition. But
now he is willing to
eat during
hospitalization
because of proper
Page 7 of 38
pagkain...”
2. Hygiene
Daughter
verbalized:
“Hindi na siya
makapag-ayos
ng sarili...”
Needs minimal
assistance in
bathing and
g
Respiratory Symptoms in the Terminally Ill PatientVITAS Healthcare
The goal of this webinar was to educate healthcare professionals on interventions for cough, dyspnea, hemoptysis, and the “death rattle” in patients with end-of-life respiratory symptoms.
The document discusses the career path and experiences of a family physician. It describes their journey from high school through medical school and residency training. As a family physician, they provide comprehensive primary care to patients of all ages, conduct a wide range of medical procedures, and value building long-term relationships with patients to support their overall health and well-being.
The document describes a case study of a 66-year-old female patient who suffered an ischemic stroke affecting the middle cerebral artery. She experienced left-sided weakness and expressive aphasia. Initial evaluation found she had oropharyngeal dysphagia and aspiration even with nectar thick liquids. She received intensive speech and swallowing therapy, making progress until being discharged to an inpatient rehabilitation facility for further recovery.
Annals of Behavioral Medicine Volume 49-Issue 1 Supplement-April 2015Monique Tsang, BS, CNA
This seminar provides an overview of a pilot bibliotherapy program for survivors of acquired brain injury (ABI) and individuals with chronic pain or disability. The program was started in 2012 at Erie County Medical Center in Buffalo, NY and has shown benefits to quality of life and symptom reduction. The seminar will present qualitative data on the impact of the program and provide details on its development, mission statement, recruitment process, book selection, and collaboration with rehabilitation and behavioral health services. Bibliotherapy shows potential as a cost-effective and sustainable treatment approach to target common deficits after ABI or injury such as reduced empathy, poor perspective taking, and impaired information processing.
Annals of behavioral medicine volume 49 issue 1 supplement april 2015Monique Tsang, BS, CNA
The current study investigated whether a single presentation on sleep hygiene could result in improvement in reported sleep quality and quantity for undergraduate students newly entering university.
This curriculum vitae summarizes Jeffrey S. Gerdes' professional experience and education. It lists that he has been the chiropractor and clinical director of Carolina ChiroCare and Rehab Inc. in Raleigh, NC since 2010. It also notes that he received his doctorate of chiropractic from Palmer College of Chiropractic Florida in 2008. The CV provides details on his licensure, certifications, and extensive postgraduate education, including courses on MRI interpretation, neurological emergencies, and assessing medical fitness to return to work.
The document summarizes a course on recent advances in the diagnosis and management of kidney cancer. The course was held on May 17, 2008 from 6-8 pm as part of the American Urological Association's annual meeting. It was directed by Dr. W. Marston Linehan from the National Cancer Institute and included presentations by Dr. Peter Pinto from the National Cancer Institute and Dr. Jeffrey Sosman from Vanderbilt University. The course provided an overview of new developments in diagnosing and treating kidney cancer.
The document summarizes a course on recent advances in the diagnosis and management of kidney cancer. The course was held on May 17, 2008 from 6-8 pm as part of the American Urological Association's annual meeting. It was directed by Dr. W. Marston Linehan from the National Cancer Institute and included presentations by Dr. Peter Pinto from the National Cancer Institute and Dr. Jeffrey Sosman from Vanderbilt University. The course aimed to provide the latest information on diagnosing and treating kidney cancer to practicing urologists.
This document provides a curriculum vitae for Dr. Jeffrey S. Gerdes that includes his contact information, occupational history as a chiropractor since 2010, education including a Doctorate of Chiropractic from Palmer College of Chiropractic in 2008, licensure information, selected postgraduate education and certifications in areas related to chiropractic and neurology, and publications.
The document announces a continuing medical education event at the University of South Alabama on Wegener's granulomatosis presented by Dr. Mario Magnone. The event objectives are to understand the pathogenesis, organ involvement, distinguishing factors, and treatment options for Wegener's granulomatosis. It is intended to increase physician knowledge and improve patient outcomes. The event offers 1 AMA PRA Category 1 Credit for participating physicians.
Discussion post reply APA Format2 references for each discussiLyndonPelletier761
This discussion post reply summarizes steps taken at Sacred Heart Hospital to reduce specimen mislabeling errors through the use of an electronic positive patient identification (EPPID) system called Collection Manager. The post discusses how previously Sacred Heart used pre-printed labels that could result in errors, but now uses Collection Manager which prints labels at the patient's bedside after their armband is scanned. This eliminates manual writing and pre-printed labels, reducing errors. The post provides examples of how Collection Manager integrates with the laboratory information system to ensure accurate labeling. It is reported that Sacred Heart saw a reduction in mislabeling errors from about 10 per year to only 1 error per year after implementing Collection Manager.
This document provides information about the 20th Annual Primary Care in Paradise conference taking place from March 23-26, 2015 in Maui, Hawaii. The conference is designed by primary care physicians for primary care physicians to present content on commonly encountered medical specialties and therapeutic areas from a primary care perspective. Over the four days, physicians will receive lectures and case studies on topics like gastroenterology, neurology, pulmonary embolism, and more to help them better diagnose, treat and manage patients. The goal is for primary care doctors to leave with practical skills and resources to apply in their own practices.
Mayo Clinic - 2011 ACC Satellite Education Symposiumswest0521
This is satellite educational symposium during the 2011 ACC Scientific Session. The program would be of interest for imaging professionals, cardiologists, radiologists, nuclear cardiology and nuclear medicine specialists and other healthcare providers interested in the application of cardiac imaging in clinical practice.
This document discusses medical errors and misdiagnosis. It notes that one in five medical errors are potentially serious or fatal, and that the most common reasons for medical malpractice claims are surgery errors and diagnostic errors. Diagnostic errors account for many preventable deaths annually in the US. Some of the leading causes of misdiagnosis discussed include lack of healthcare professionals, poor teamwork and follow up, human cognitive factors, and too much focus on one exam finding. The document also provides strategies to reduce errors such as thorough history taking, physical exams, using diagnostic aids, and always following up on concerning symptoms.
This document provides information about a continuing medical education event at the University of South Alabama on atypical motor neuron diseases. The event will feature a lecture by Dr. Bassam Bassam on atypical motor neuron diseases. The objectives are to learn the criteria for diagnosing motor neuron disease, be aware of subtypes and their presentations, and learn about the clinical features, etiology, diagnosis, prognosis and management of atypical forms. The target audience is neurologists, physicians, students and other healthcare professionals interested in neurological diseases. The event aims to increase knowledge and improve patient outcomes.
1. The document announces a continuing medical education event at the University of South Alabama about Wegener's granulomatosis.
2. The event will feature a lecture by Dr. Mario Magnone on understanding the pathogenesis and organ involvement of Wegener's disease and distinguishing it from other conditions.
3. Attendees can earn 1 AMA PRA Category 1 credit and the event aims to improve healthcare for patients by addressing competence and conveying updated information on internal medicine topics.
1. The document announces a continuing medical education event at the University of South Alabama discussing Wegener's granulomatosis.
2. The event will be led by Dr. Mario Magnone and cover the pathogenesis, organ involvement, distinguishing factors from other conditions, and treatment options for Wegener's granulomatosis.
3. Attendees can earn 1 AMA PRA Category 1 credit and the event aims to improve healthcare quality by addressing knowledge gaps and conveying updated information on internal medicine topics.
René Hernandez Cardenaché's curriculum vitae outlines his educational background and clinical experience. He received his doctorate in clinical psychology from Pepperdine University and is currently an Assistant Professor of Psychiatry and Clinical Neuropsychology at the University of Miami. The CV details his research, teaching, clinical consultation work, and roles directing fellowship programs and serving on dissertation committees.
Brain Health: The Importance of Recognizing Cognitive Impairment: An IAGG Con...Nutricia
This document summarizes the conclusions of an expert panel convened by the International Association of Gerontology and Geriatrics to discuss early detection of cognitive impairment. The panel agreed that:
1) Validated screening tests that take 3 to 7 minutes can identify early cognitive impairment.
2) The most effective approach is to use both patient-reported and informant-reported screening tools.
3) Early cognitive impairment may have treatable components, and emerging evidence supports interventions like medical treatment, nutrition changes, and physical/cognitive exercise to delay or reduce decline.
This document provides copyright information and permissions details for the book "Pediatric Neurology: Principles & Practice". It lists the publishers, copyright dates from 1999-2006, and details that no part of the publication may be reproduced without permission. It also notes that medical knowledge is constantly changing and readers should check for latest information from manufacturers when administering treatments. The Library of Congress cataloging information is provided.
A short course in epidemiology for cliniciansSurya Rao
This document provides an overview of a short course in epidemiology for clinicians. The course aims to help clinicians understand how epidemiological concepts can enhance clinical practice by applying principles to decision making, risk assessment, interpreting tests and literature. It covers topics like study designs, statistical analysis, biases and applying evidence-based practices. The 5 modules include sessions on epidemiology applications in clinics, evidence-based medicine, epidemiological methods, statistical concepts and getting started in research. Overall, the course aims to equip clinicians with skills in epidemiology, evidence interpretation and undertaking clinical research.
A New Perspective On Survival Outcomes In Multiple SclerosisJustin Knight
This document discusses new findings on survival outcomes in multiple sclerosis (MS) from international registries and databases. It summarizes that MS patients have a mean decrease in survival time of 6 to 12 years compared to the general population. A 21-year follow-up study of interferon beta-1b treatment showed that early treatment may positively impact long-term mortality rates in MS patients compared to delayed treatment. The findings suggest that early and continued disease-modifying treatment may improve long-term survival outcomes for individuals with MS.
The document provides information about the Healthcare AsiaPacific 2017 conference to be held in Kuala Lumpur, Malaysia from July 03-05, 2017. The conference will bring together over 500 participants from around the world to present on topics related to healthcare through keynote lectures, oral presentations and poster sessions. It provides details on registration, the conference schedule with sessions over three days, information on publishing accepted abstracts in journals, and background on the host city of Kuala Lumpur.
This document summarizes the results of a study examining factors that influence multiple sclerosis (MS) patients' willingness to participate in clinical trials. The study involved questionnaires assessing patients' knowledge of and attitudes towards clinical trials. The results showed that about half of MS patients were willing to consider participating in a trial. The strongest positive predictors of willingness were older age, not having children, progressive MS, and previous trial participation. Risk of side effects was the top negative factor influencing participation. Providing comprehensive information to patients was the most important solution to increase participation.
Next Generation Dx Summit 2015 - Moving Assays to the ClinicJames Prudhomme
The Next Generation Dx Summit, entering its seventh year, brings together more than 800 diagnostics professionals from across the world, providing comprehensive programming and valuable networking opportunities. Spanning from clinical diagnostics to business strategy, this year’s expanded program encompasses predictive cancer biomarkers, companion diagnostics, infectious disease, point-of-care, pharmacy-based diagnostics, cell-free DNA, commercialization, cancer immunotherapy, and reimbursement. With widespread coverage of all the most relevant diagnostics topics, the Next Generation Dx Summit promises to be a must-attend event to hear the latest announcements and developments in this rapidly evolving field.
Robin Murray commentary during the SRF webinar "Is Schizophrenia Dead Yet?"wef
Schizophrenia is not a single disease but rather two different syndromes according to the DSM-5 and ICD-10 diagnostic criteria, with only 70% of patients meeting criteria for both. This raises questions about what to call patients who meet one but not the other and how useful the term "schizophrenia" is given the lack of biological markers and different interpretations by psychiatrists. Looking at dimensions of psychosis symptoms, predominant causes, and severity/persistence may provide more helpful information to patients and their outcomes than the term schizophrenia.
Eske Derks commentary - SRF webinar "Is Schizophrenia Dead Yet?"wef
Schizophrenia patients are qualitatively different from their healthy siblings and controls based on genetic studies. While there is some genetic overlap between schizophrenia, psychosis, and general mental health risk, distinct genetic factors for schizophrenia have also been found. Specifically, over 200 genetic risk factors for schizophrenia have been identified. Based on these genetic findings, the presenter concludes that schizophrenia is not simply an extreme on a normal distribution of traits and replacing it with a psychosis spectrum disorder would be premature.
Jim van Os presentation during SRF live webinar "Is Schizophrenia Dead Yet?"wef
This document discusses the debate around schizophrenia diagnoses and proposes an alternative psychosis spectrum syndrome approach. It summarizes that the debate is about clinical diagnosis, not research criteria. It also notes that around 3.5% of people experience some form of psychosis, but the current system publishes overwhelmingly on only one category, schizophrenia. The document advocates for recognizing a spectrum approach and dimensional personal diagnoses within a categorical psychosis spectrum to better reflect individuals' experiences and needs.
Rene Kahn commentary during SRF Live Webinar: "Is Schizophrenia Dead Yet?wef
Schizophrenia and bipolar disorder are distinct conditions with little genetic overlap and different risk factors. Schizophrenia is primarily a cognitive disorder, not defined by psychosis, as cognitive decline precedes psychotic episodes. While some wish to deny the poor prognosis of schizophrenia, studies show the disorder leads to reduced life expectancy, high suicide and unemployment rates, and long-term functional impairment for most patients.
NIMH i PSC Assays for the Drug Pipeline - Panchisionwef
Dr David Panchision's live presentation at the Schizophrenia Research Forum's live webinar of June 28, 2017 - http://www.schizophreniaforum.org/forums/webinar-modeling-neuropsychiatric-disorders-using-vitro-models
Schizophrenia Research Forum Live Webinar - June 28, 2017 - Rusty Gage wef
1) The document describes a study using induced pluripotent stem cells (iPSCs) derived from bipolar disorder (BD) patients to model the disease in vitro.
2) Hippocampal dentate gyrus-like neurons were differentiated from iPSCs and showed hyper-excitability at both the molecular and functional levels in BD-derived neurons.
3) Treatment with lithium rescued the hyper-excitability phenotype in neurons derived from lithium-responsive BD patients but not lithium non-responsive patients, suggesting patient-specific responses.
SCHIZOPHRENIA RESEARCH FORUM - LIVE WEBINAR June 2017 Kristen Brennandwef
Kristen Brennand presentation at the live webinar of June 28, 2017 hosted by the Schizophrenia Research Forum (http://www.schizophreniaforum.org/forums/webinar-modeling-neuropsychiatric-disorders-using-vitro-models)
STRATEGIES FOR COMMUNICATION AND SENSITIVITY FOR PERSONS EXPERIENCING DEMENTI...wef
This document summarizes a workshop on strategies for communicating with persons experiencing dementia. It discusses how communication is impacted at different stages of dementia from early to late stage. In early stage, word retrieval becomes difficult. In middle stage, language abilities further decline making conversation challenging. In late stage, communication is limited but sensory stimulation through touch, sound, and smell can still connect a person. The workshop provides guidance on adapting approaches to best communicate with someone based on their stage of dementia.
Translating from Animal Models to Human Schizophrenia - Insights into Pathoph...wef
Presentation made by Dr. Tony Grace at the Schizophrenia Research Forum's live webinar of May 4, 2017 - Dopamine in Schizophrenia—Cortical and Subcortical Pathophysiology - review recording of session at http://www.schizophreniaforum.org/forums/dopamine-schizophrenia%E2%80%94cortical-and-subcortical-pathophysiology
Presentation made by Dr. Oliver Howes at the Schizophrenia Research Forum's live webinar of May 4, 2017 - Dopamine in Schizophrenia—Cortical and Subcortical Pathophysiology - review recording of session at http://www.schizophreniaforum.org/forums/dopamine-schizophrenia%E2%80%94cortical-and-subcortical-pathophysiology
Topography and functional significance of the dopaminesgic dysfunction in sch...wef
Presentation made by Dr. Anissa Abi-Dargham at the Schizophrenia Research Forum's live webinar of May 4, 2017 - Dopamine in Schizophrenia—Cortical and Subcortical Pathophysiology - review recording of session at http://www.schizophreniaforum.org/forums/dopamine-schizophrenia%E2%80%94cortical-and-subcortical-pathophysiology
SRF Webinar - What It Will Take to Make Coordinated Specialty Care Available ...wef
Presentation made March 22, 2017, during the live webinar hosted by Schizophrenia Research Forum (SRF). Event recording and additional slides at http://www.schizophreniaforum.org/forums/achieving-effective-treatment-early-psychosis-united-states
SRF Webinar: Beyond DUP - Addressing Disengagement in Community-based Early I...wef
Presentation made March 22, 2017, during the live webinar hosted by Schizophrenia Research Forum (SRF). Event recording and additional slides at http://www.schizophreniaforum.org/forums/achieving-effective-treatment-early-psychosis-united-states
This document provides an overview of memory loss, dementia, and Alzheimer's disease. It defines key terms, describes symptoms at different stages of dementia, and discusses a person-centered approach to care. The main points are:
1) Dementia is not a specific disease but a general term for symptoms caused by various brain disorders, while Alzheimer's disease is the most common cause of progressive dementia.
2) Early stage dementia symptoms include memory loss, impaired judgment, and difficulty completing tasks, while middle and late stage symptoms involve greater impairment and dependence on others for care.
3) A person-centered approach focuses on maintaining an individual's dignity, independence, and identity through techniques like validation, respect, and personalized
Presentation made at the live webinar hosted by the Schizophrenia Research Forum on the 21st of February, 2017 - http://www.schizophreniaforum.org/forums/treatment-resistant-schizophrenia-new-guidelines-diagnosis-and-terminology
Oliver Howes - Treatment-Resistant Schizophrenia: New Guidelines on Diagnosis...wef
Presentation made at the live webinar hosted by the Schizophrenia Research Forum on the 21st of February, 2017 - http://www.schizophreniaforum.org/forums/treatment-resistant-schizophrenia-new-guidelines-diagnosis-and-terminology
John Kane - Treatment-Resistant Schizophrenia: New Guidelines on Diagnosis an...wef
Presentation made at the live webinar hosted by the Schizophrenia Research Forum on the 21st of February, 2017 - http://www.schizophreniaforum.org/forums/treatment-resistant-schizophrenia-new-guidelines-diagnosis-and-terminology
HEAR approach to behavior management Live webinar Feb 1 2017wef
Slides presented at the HEAR Approach to Behavior Management live webinar of February 1, 2017, featuring presentations from Dr. Andrew Heck and Carol Garby.
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
1. Warren Barker
Wien Center for Alzheimer’s Disease
& Memory Disorders
Mount Sinai Medical Center
Phone: 305-674-2592 Fax: 305-674-2996
8TH
ANNUAL
MCISYMPOSIUM
For information please visit:
www.mcisymposium.org
or
Email: info@mcisymposium.org
March 12 -13
2010
Save the Date!
Accreditation
Mount Sinai Medical Center is
accredited by the Accreditation
Council for Continuing Medical
Education (ACCME) to sponsor
continuing medical education for
physicians. Mount Sinai designates
this educational activity for a
maximum of 11 AMA PRA
Category 1 Credits. Physicians
should only claim credit
commensurate with the extent of
their participation in the activity.
Psychology Credit
The Symposium on Early
Alzheimer’s Disease has been
approved by the Florida Board of
Psychology and the Miami Area
Geriatric Education Center
(MAGEC). This program has been
approved for 11 contact hours.
(MAGEC CE Broker Tracking
#20-252935).
Disclosure Statement
Faculty relationship(s) with industry will be disclosed and available in the Symposium
Syllabus and at the meeting site. In addition, disclosure to the audience will be made
by the Faculty prior to their presentations.
Mount Sinai Medical Center in accordance with the Standards for Commercial
Support of the Accreditation Council for Continuing Medical Education (ACCME) will
disclose the existence of any significant financial interest or other relationship that a
faculty member/spouse or partner has (1) with the manufacturer(s) of any
commercial product(s) and/or provider(s) of commercial services and (2) with any
commercial supporters of the activity. Faculty is also required to disclose to the
audience, during their presentation, any investigational/unlabeled use that is
discussed.The intent of this disclosure is not to prevent a speaker with a significant
financial or other relationship from making a presentation, but rather to provide the
attendees with information on which they can make their own judgments.
Symposium Information
Please contact one of the following:
Wien Center
4300 Alton Road
Miami Beach, FL 33140
Presented By:
Mount Sinai Medical Center, Miami Beach, Florida
FRIDAY – SATURDAY March 12 - 13, 2010
Symposium Location:
Eden Roc Hotel
4525 Collins Avenue
Miami Beach, FL 33140
Program Director:
Ranjan Duara, MD
Medical Director, Wien Center for Alzheimer’s Disease and Memory Disorders
Mount Sinai Medical Center, Miami Beach, FL
8TH
ANNUAL
MARK YOUR CALENDAR
Symposium on
Early Alzheimer’s
Disease
MILD COGNITIVE IMPAIRMENT (MCI) SYMPOSIUM
Theme for 2010: Focus on Early and Preclinical Alzheimers Disease
www.mcisymposium.org
Yirah Ochoa
Wien Center for Alzheimer’s Disease
& Memory Disorders
Mount Sinai Medical Center
Phone: 305-674-2259
Email: mcisymposium@msmc.com
E-mail: info@mcisymposium.org
Web: www.mcisymposium.org
2. Distinguished Faculty
Program Director
Ranjan Duara, MD
Medical Director, Wien Center for Alzheimer’s Disease and Memory Disorders
Mount Sinai Medical Center, Miami Beach
Departments of Medicine, Neurology and Psychiatry
Miller School of Medicine, University of Miami, Miami, FL
Department of Neurology, University of South Florida College of Medicine, Tampa, FL
Needs Assessment
Unless ways are found to prevent
Alzheimer’s Disease (AD) or delay its onset,
it is projected that 13 million people in the
United States will have AD by 2050.
Individuals with AD suffer from cognitive and
functional impairment, loss of productivity
and significant deterioration in over-all
quality of life. Most will develop problematic
behaviors and many will need long-term
care. In addition, caregivers of the patients
are often affected by physical burden,
emotional distress and financial hardship.
Since the development of criteria for AD
almost twenty-five years ago, there have
been major advances in our understanding
of the biology and early clinical features of
AD and other causes of dementia. This has
led to improvements in clinical assessment
and brain imaging, which has enabled
clinicians to diagnose AD more reliably and
at an earlier stage of illness. Patients
classified as having a pre-dementia condition
known as Mild Cognitive Impairment (MCI)
are at increased risk for progressing to AD
or dementia. Thus, American Academy of
Neurology Practice Guidelines recommend
that clinicians identify and monitor MCI
using cognitive test batteries. The early
diagnosis of dementing illnesses can lead to
beneficial pharmacological treatment and
non-pharmacological interventions
(e.g., caregiver education, legal and
financial counseling).
However, several studies have shown that
physicians often lack knowledge of the early
signs and symptoms of AD resulting in a
delay in diagnosis and intervention. Many
physicians are also unaware of the
advantages and limitations of new
assessment tools, or how to interpret their
results in clinical practice. Clinicians also
need information about the latest AD
research to respond to patient questions and
to refer to clinical trials.
Target Audience
This activity is designed for:
➢ Neurologists
➢ Psychiatrists
➢ Geriatricians & Gerontologists
➢ Epidemiologists
➢ Neuropsychologists
➢ Psychologists
➢ Neuroscientists
Educational Objectives
The purpose of this symposium is to provide a forum for
new information and for in-depth discussions about
advances in research, related to the clinical diagnosis,
progression and treatment of Alzheimer’s Disease. This
symposium will emphasize the early stage of AD and
the preclinical deficits that are associated with
increased risk for subsequent dementia.
We will examine recent developments in understanding
risk factors which lay the groundwork for potential
strategies for treating and delaying Alzheimer’s
disease. We will present results from several
longitudinal and cross-sectional studies that have
explored clinical, imaging and biomarkers factors that
are related to AD.
The symposium will include two keynote addresses and
four individually themed symposia, each featuring
national experts in the fields of neurology, psychiatry,
geriatrics, neuropsychology, radiology, epidemiology,
genetics and pharmacology. Each mini-symposium will
be followed by an extended discussion period,
allowing active audience participation to promote a
better understanding of the issues.
Upon completion of this symposium, the attendees
should be able to:
• Describe the rationale for a preclinical AD diagnosis.
• Name preclinical factors that increase the risk for
subsequent AD or dementia.
• Discuss the results of clinical drug studies and
strategies to enrich prevention trials.
• Recognize the difference and similarities between
amnestic and non-amnestic MCI.
• Understand the challenges in interpreting the results
of psychometric tests in MCI and early AD.
Keynote Speakers:
Mark W. Bondi, Ph.D., ABPP/CN
Professor of Psychiatry
VA San Diego Healthcare System
University of California
San Diego, California
John Morris, MD
Friedman Distinguished Professor of
Neurology
Washington University School of Medicine
St. Louis, Missouri
Distinguished Faculty:
Rhoda Au, PhD
Associate Professor of Neurology
Boston University School of Medicine
Boston, Massachusetts
Richard J. Caselli, MD
Professor and Chair, Department of
Neurology
Clinical Core Director, Arizona Alzheimer's
Disease Center
Mayo Clinic Arizona
Scottsdale, Arizona
Katherine (Nutter-Upham) Eskine, MA
PhD Candidate in the Cognition Brain and
Behavior Program
City University of New York
Brooklyn, New York
Norman L. Foster, M.D.
Professor of Neurology
Director, Center for Alzheimer’s Care,
Imaging and Research
Senior Investigator, The Brain Institute at The
University of Utah
Salt Lake City, Utah
Mary Ganguli, MD, MPH
Professor of Psychiatry and Epidemiology
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Robert C. Green, MD, MPH
Professor of Neurology, Genetics, and
Epidemiology
Boston University School of Medicine
Director, Boston University Alzheimer’s
Disease Clinical and Research Program
Boston, Massachusetts
Amy Jak, Ph.D.
Assistant Professor of Psychiatry
University of California, San Diego, School
of Medicine
Director, TBI Cognitive Rehabilitation Clinic,
VA San Diego Healthcare System
San Diego, California
David Loewenstein PhD, ABPP/CN
Professor of Psychiatry and Behavioral
Sciences and Neurology,
University of Miami Miller School of
Medicine
Wien Center for Alzheimer’s Disease and
Memory Disorders, Mount Sinai
Miami, Florida
Jennifer J. Manly, PhD
Associate Professor of Neuropsychology
Taub Institute for Research on Alzheimer's
Disease and the Aging Brain
Columbia University Medical Center
New York City, New York
Lisa Mosconi, PhD
Assistant Professor of Psychiatry
PET Imaging Research Director, Center for
Brain Health
New York University School of Medicine
New York City, New York
Ronald Petersen, MD, PhD
Professor of Neurology and Alzheimer’s
Disease Research
Mayo Medical School
Rochester, Minnesota
Joseph Quinn, MD
Co-Director, Northwest Parkinson’s Disease
Research, Education and Clinical Centers
Associate Professor, Department of
Neurology
Oregon Health & Science University
Portland, Oregon
Catherine M. Roe, PhD
Research Instructor
Alzheimer's Disease Research Center
Washington University School of Medicine
St. Louis, Missouri
Eric Siemers, MD
Medical Director, Alzheimer's Disease Team
Lilly Corporate Center, Eli Lilly and Company
Indianapolis, Indiana
Reisa Sperling, M.D.
Associate Professor of Neurology, Harvard
Medical School
Director of Clinical Research, Memory
Disorders Unit
Brigham and Women's Hospital
Boston, Massachusetts
3. AM
7:30 - 8:30 Breakfast Buffet
8:30 - 9:15 Keynote Address: Amnestic and
Non-amnestic MCI are Distinct Entities –
Fact or Fiction?
Mark Bondi, PhD
9:15 - 9:30 Break
9:30 - 11:30 Mini-Symposium: Challenges in Interpreting
Psychometric Test Results in Early AD, MCI
and PreMCI
Chair: Mary Ganguli, MD
PreMCI, Alzheimer’s Disease and
Cognitive Reserve
Catherine Roe, PhD
Verbal Fluency and Executive Function in
MCI and Subjects with Cognitive
Complaints
Katherine Nutter-Upham, MA
Quantification of Neuropsychological
Approaches to Defining MCI Subtypes
Amy Jak, PhD
Assessment of Cognitive Impairment in
Minority Population
Jennifer Manly, PhD
11:30 - 11:45 Break
11:45 - 12:30 Open Discussion
12:30 Adjourn
Saturday, March 13, 2010
PM
1:15 - 2:30 Lunch Break
2:30 - 4:15 Mini-Symposium: Biomarkers for Early AD,
MCI and PreMCI
Chair: TBD
FDG-PET Imaging in the Evaluation of Very
Early AD: Contributions of the Alzheimer’s
Disease Neuroimaging Initiative (ADNI)
Norman Foster, MD
Amyloid Imaging and fMRI studies in
Early AD
Reisa Sperling, MD
Cerebral Glucose Metabolism in PreClinical
AD with Maternal Family History of AD
Lisa Mosconi, PhD
4:15 - 5:00 Open Discussion
Friday, March 12, 2010
AM
7:00-8:00 Breakfast Buffet
8:00-8:15 Welcome and Introduction
Ranjan Duara MD
9:00 - 10:30 Mini-Symposium: PreClinical AD:
Longitudinal Studies Chair:
Ronald Petersen, MD, PhD
The preclinical phase of Alzheimer
disease: A 20-year prospective study
of the Framingham Cohort
Rhoda Au, PhD
Longitudinal Cognitive Changes in
PreMCI states: Effect of Clinical,
Imaging and Genetic Factors
Richard Caselli, MD
2-4 year outcome of PreMCI states in
the Florida ADRC
David Loewenstein, PhD
10:30 - 11:00 Open Discussion
11:00 - 11:15 Break
11:15 - 12:30 Mini-Symposium: Clinical Trials and
Genetics of AD
Chair: Eric Siemers, MD
Enriching Future Prevention Trials
with Genetic Risk Assessment and
Disclosure
Robert C. Green, MD, MPH
Significance of the MIDAS and ADCS
trials with DHA for Secondary
Prevention and Treatment of AD
Joseph Quinn, MD
The Future of Clinical Trials for
Treatment and Prevention of AD
Eric Siemers, MD
12:30 - 1:15 Open Discussion
Scientific Agenda
4. SYMPOSIUM ON EARLY ALZHEIMER’S DISEASE
THREE EASY WAYS TO REGISTER FOR THE EARLY ALZHEIMER’S DISEASE SYMPOSIUM 2010:
ONLINE: FAX: MAIL:
www.mcisymposium.org Attn: Warren Barker Warren Barker
(305) 674-2996 Wien Ctr
4300 Alton Road
Miami Beach, FL 33140
REGISTRANT INFORMATION Please print:
_________________________________________________________________________________________
LAST NAME FIRST NAME MIDDLE NAME
DEGREE: MD DO PhD OTHER
_________________________________________________________________________________________
INSTITUTION / ORGANIZATION
__________________________________________________________________________________________________________________________________
STREET ADDRESS
________________________________________________________________________________________________________________________________
CITY STATE ZIP CODE COUNTRY
________________________________________________________________________________________________________________________________
E-MAIL TELEPHONE
REGISTRATION FEES:
Physicians: $340.00 (if dated/postmarked by February 21)
$390.00 (if dated/postmarked after February 21)
$440.00 (on site registration)
Non-Physicians: $225.00 (if dated/postmarked by February 21)
$275.00 (if dated/postmarked after February 21)
$325.00 (on site registration)
Students: $100.00
PAYMENT METHOD:
American Express Master Card Visa Check in the amount of _____________
Card No. _______________________________________________ Expiration Date _____/_____
Cardholder’s Name _________________________________________________________________
Signature __________________________________________________________________________
________________________________________________________________________________________________________________________________
NAME & ADDRESS ON CARD IF DIFFERENT THAN ABOVE
________________________________________________________________________________________________________________________________
Payment must accompany registration form. Refund Policy: Full refund will be given if written notice
is received not later than February 21,2010. All refunds will be processed after the meeting.
Method of Registration
To register by mail or fax:
please complete the registration form and
send it with the payment to the above mailing
address or fax number.
To register by email:
provide the information requested on the
registration form in an e-mail message and
send to: mcisymposium@msmc.com
To register by internet:
www.mcisymposium.org
Registration confirmations will be issued.
Payment:
Registration fees can be paid by credit card
or check, no cash is accepted.
Please make all checks payable to:
MOUNT SINAI MEDICAL CENTER
Registration Fee Inclusions:
Registration fees include admittance to all
the scientific conferences, conference
materials, breakfast, lunch on the first day,
refreshment breaks.
Registration Hours:
The conference registration desk will
be staffed:
Thursday, March 11 4:00 pm – 7:00pm
Friday, March 12 7:00 am - 5:00 pm
Saturday, March 13 7:30 am - 12:30 pm
Registration Information
Symposium Location
Eden Roc Hotel:
4525 Collins Avenue, Miami Beach, Florida 33140
Phone: (800) 468-3571 or (305) 531-0000
Web-Site: www.marriott.com/miasr
The place to experience Miami Beach… On
magnificently landscaped oceanfront grounds,
the new Eden Roc brings dynamic design,
unsurpassed luxury and cutting-edge
technology together in one place – the place
to be on Miami Beach.
Following a $200
million dollar
renovation and
expansion, the bold
new Eden Roc, A
Renaissance Beach
Resort and Spa, embraces it role as a timeless
treasure, yet welcomes guests with a contemporary spirit. In this
stunning locale, a pulsing nightlife, brilliant white-sand beaches, and
sizzling culture combine for the perfect getaway. At the Eden Roc
Hotel you will savor the best of this colorful city.
DRESS
Business casual attire is appropriate for all events. A light sweater or jacket
is recommended in the meeting rooms.
Hotel Reservations
For the convenience of the 8th Annual Symposium on early Alzheimer’s
Disease attendees, a limited number of rooms have been reserved at the
special daily rate of $200 (single or double occupancy, plus resort fees,
state and local taxes). To receive this conference rate, reservations must be
made directly with the Eden Roc Hotel and you must mention that you are a
registrant of the 8th Annual Symposium on Early Alzheimer’s Disease.
Rooms will be held at the special rate until Thursday, February 18, 2010.
Rooms at the discounted rate will be allocated on a first-come, first-served
basis. Reservations received after the cut-off date are subject to availability
and prevailing rates.
Mount Sinai Medical Center is committed to making its CME activities
accessible to all individuals. If you are in need of an accommodation, please
do not hesitate to call and/or submit a description of your needs in writing
within 5 weeks of the activity in order to receive service.
FOR ROOM RESERVATIONS CALL: (800) 468-3571 or (305) 531-0000
OR ACCESS THE HOTEL WEB SITE VIA www.marriott.com/miasr
8TH
ANNUAL
MARK YOUR CALENDAR